Navigation Links
DHHS Guidelines Support Use of Trofile(TM) Assay Prior to CCR5 Inhibitor Use
Date:2/4/2008

SOUTH SAN FRANCISCO, Calif., Feb. 4 /PRNewswire-FirstCall/ -- Monogram Biosciences, Inc. (Nasdaq: MGRM) today announced that guidelines issued by the Department of Health and Human Services (DHHS) recommend that a co-receptor tropism test, such as Monogram's Trofile(TM) assay, should be performed whenever the use of a CCR5 inhibitor is being considered and might also be considered for patients who exhibit virologic failure on a CCR5 inhibitor.

The Panel on Antiretroviral Guidelines for Adult and Adolescents guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents, Department of Health and Human Services, January 29, 2008, were developed by a working group of the Office of AIDS Research Advisory Counsel, the National Institutes of Health advisory body on HIV research and treatment policy and initiatives. These guidelines follow the FDA's instructions on Selzentry's label, which call for tropism testing prior to prescribing the drug. Pfizer's Selzentry(TM) (maraviroc) is the first CCR5 inhibitor to receive FDA approval.

"The Office of AIDS Research recommendations and DHHS guidelines underscore the importance of using a clinically validated tropism test to determine whether a patient should be treated with a CCR5 inhibitor," said Monogram Biosciences CEO William Young. "Our Trofile assay is the only test currently available that can provide accurate, reproducible results to guide treatment with this new class of medications."

Monogram's Trofile(TM) assay was used to select patients for participation in the pivotal clinical trials that formed the basis of approval for Selzentry and is being used in every advanced CCR5 inhibitor development program currently underway. In addition to calling
'/>"/>

SOURCE Monogram Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Ranexa(R) Added to New ACC/AHA Guidelines on Unstable Angina/Non ST-Elevation Myocardial Infarction (UA/NSTEMI)
2. Interim Analysis Supports Continuation of Cell Genesys VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer
3. Interim Safety Analysis Supports Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma
4. PNH Patients With Lower Levels of Hemolysis, Mild Anemia and Minimal Transfusion Support Have Significant Disease Burden; Soliris(R) Therapy Provided Clinical Improvements in PNH Patients Regardless of Disease Severity
5. New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma
6. Pharsight Uses FDA Disease Model to Support Oncology Drug Development
7. Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood
8. New Data from the Framingham Heart Study Supports PAT Technology to Diagnose Early Cardiovascular Disease
9. Cost-Effectiveness Study Supports Use of EUFLEXXA(TM) by Rheumatologists for Pain Relief in Patients with Knee Osteoarthritis
10. Consumer Advocates Support Patent Office on Stem Cell Patent Rejection
11. SAIC Awarded Malaria Vaccine Production Support Contract Extension by the National Institute of Allergy and Infectious Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Wigan and Leigh NHS Foundation ... are delighted to announce WWL,s decision to implement the ... The system will be implemented across all three WWL ... healthcare in the future. WWL chose ... on-budget system implementations as well as its proven track ...
(Date:9/30/2014)... Sept. 30, 2014 MiMedx Group, Inc. (NASDAQ: ... utilizing human amniotic tissue and patent-protected processes to develop ... Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental ... , Ph.D., Chief Scientific Officer, will present at the ... present on Tuesday, October 7, 2014, at 5:00PM Pacific ...
(Date:9/30/2014)... This study provides an analysis of ... including nuclear imaging informatics, PET imaging informatics, and ... the size of the market based on its ... future growth based on the current drivers and ... in the broader markets for imaging equipment, advanced ...
Breaking Medicine Technology:Wrightington, Wigan and Leigh NHS Foundation Trust selects Allscripts Sunrise 2Wrightington, Wigan and Leigh NHS Foundation Trust selects Allscripts Sunrise 3Wrightington, Wigan and Leigh NHS Foundation Trust selects Allscripts Sunrise 4MiMedx to Present at the Stem Cell Meeting on the Mesa 2Analysis of the US Molecular Imaging Informatics Market 2Analysis of the US Molecular Imaging Informatics Market 3
... Wound Management Technologies, Inc. (OTC Bulletin Board: ... Innovations, LLC has added the company,s first pharmacy client ... Inc. of Fort Worth, TX is an independent pharmacy ... in wound care, long term care and specialty compounded ...
... Oct. 5 Express Scripts (Nasdaq: ESRX ... business unit to create a new independent, nonprofit charitable ... medicines for low-income, uninsured Americans and working families. ... Express Scripts, leads the new national organization, which has ...
Cached Medicine Technology:All-Time High in Q Orders for Wound Management Technologies, Inc. 2All-Time High in Q Orders for Wound Management Technologies, Inc. 3Express Scripts Completes Spinoff of Rx Outreach 2
(Date:10/1/2014)... October 01, 2014 Insuranceragents.info has ... a good life insurance plan for vulnerable family members. ... vulnerable family members. Providers in the family should always ... cause financial hardships for the rest of the family. ... policies. Families can benefit more from temporary coverage or ...
(Date:10/1/2014)... First Warning Systems, a pioneer in early cancer ... body, announced the company is changing its name to ... of upcoming product releases. The initial focus will be ... initial focus will be an ‘Internet of Everthing,’ wearable ... changes over time,” said Rob Royea, president and CEO ...
(Date:10/1/2014)... FARMINGTON, Conn. (PRWEB) October 01, 2014 ... its company, including a redefined mission and visual ... the power of partnering with them to create ... more agile brand that focuses on empowering customers ... benefits communications. , The crown jewel of the ...
(Date:10/1/2014)... California (PRWEB) October 01, 2014 Beverly ... Dr. Kathleen Mojas is celebrating 20 years of private ... assisted hundreds of people to achieve greater joy and ... important list of warning signs and suggestions for anyone ... Dr. Mojas explains: “Believe it or not, it’s ...
(Date:10/1/2014)... 01, 2014 Diet Doc understands that many ... lose weight and their dieting attempts could be easily sabotaged ... hormone diet treatments into their programs as a ... see fast and effective weight loss results, it also allows ... habits to maintain their weight for the future. , Earlier ...
Breaking Medicine News(10 mins):Health News:Life Insurance for Families - Clients Can Compare Affordable Rates Online! 2Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 2Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 3Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 4Health News:Farmington Company Launches Rebrand and New Positioning 2Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 2Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 3Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 2Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 3Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 4
... has opened the way for a new generation of drugs to ... tumors. ,Scientists have carried out the widest survey ... findings will be used to design anti-cancer drugs targeted at counteracting ... to result from an accumulation of mutations in one or another ...
... found naturally in oily fish, could help develop their brain, ... ,Professor Basant Puri from Imperial College, London, carried out ... and 13, who were overweight, reported the online edition of ... to look at the effects of junk food on young ...
... an extension of the advice most of us have grown ... research has suggested that beta carotene pills may not be ... related macular degeneration is common amongst the older generation, which ... might seem like a bolt from the blue, but carrots, ...
... – A certain batch of peanut butter, bought as early ... been ordered// off the shelf by the U.S. Food and ... butter is behind the outbreak of salmonella. ,Earlier, ... Peter Pan peanut butter bought since May 2006, including the ...
... be possible to wipe out memories selectively from the human ... have been able// to wipe out a single specific memory ... recollections intact. ,If that experiment can be ... be possible to help relieve sufferers of the Post-traumatic Stress ...
... reported thirteen fresh cases of bird flu, taking the total ... Assadullah Azhari, a spokesman for the United Nations Food and ... to suffer the lethal H5N1 strain of bird flu. ... forbidden the import of poultry products from Pakistan and other ...
Cached Medicine News:Health News:Gene Study Offers Hope of Potent Anti-cancer Drugs 2
... over a wide range of concentration, ... more thorough characterization than other methods. ... relative change in the distribution of ... to measure heterogeneity, stoichiometry and self-associating ...
Intended for the quantitative determination of triglycerides in serum or plasma. Reaction: endpoint. Wavelength: 520 nm. Linearity: 1000 mg/dL (11.3 mmol/L). Single vial, dry powder reagent....
Alkaline phosphatase FS (DGKC new; 37C). For determination of alkaline phosphatase (ALP) in serum or plasma. For Hitachi 717. Controls: Trulab N and Trulab P....
For the quantitative determination of alkaline phosphatase in human serum....
Medicine Products: